Amicus Therapeutics Inc (FOLD)
9.68
-0.41
(-4.06%)
USD |
NASDAQ |
Nov 15, 16:00
9.675
0.00 (0.00%)
After-Hours: 20:00
Amicus Therapeutics Research and Development Expense (TTM): 114.20M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 114.20M |
| June 30, 2024 | 128.74M |
| March 31, 2024 | 139.21M |
| December 31, 2023 | 152.38M |
| September 30, 2023 | 181.22M |
| June 30, 2023 | 193.49M |
| March 31, 2023 | 236.66M |
| December 31, 2022 | 276.68M |
| September 30, 2022 | 298.40M |
| June 30, 2022 | 304.76M |
| March 31, 2022 | 289.45M |
| December 31, 2021 | 272.05M |
| September 30, 2021 | 265.75M |
| June 30, 2021 | 276.83M |
| March 31, 2021 | 283.44M |
| December 31, 2020 | 308.44M |
| September 30, 2020 | 321.06M |
| June 30, 2020 | 309.54M |
| March 31, 2020 | 310.90M |
| December 31, 2019 | 286.38M |
| September 30, 2019 | 251.68M |
| June 30, 2019 | 331.02M |
| March 31, 2019 | 294.70M |
| December 31, 2018 | 270.90M |
| September 30, 2018 | 259.49M |
| Date | Value |
|---|---|
| June 30, 2018 | 161.91M |
| March 31, 2018 | 159.23M |
| December 31, 2017 | 149.31M |
| September 30, 2017 | 134.13M |
| June 30, 2017 | 125.95M |
| March 31, 2017 | 112.24M |
| December 31, 2016 | 104.79M |
| September 30, 2016 | 96.79M |
| June 30, 2016 | 85.30M |
| March 31, 2016 | 84.26M |
| December 31, 2015 | 76.94M |
| September 30, 2015 | 69.92M |
| June 30, 2015 | 61.00M |
| March 31, 2015 | 53.74M |
| December 31, 2014 | 47.62M |
| September 30, 2014 | 41.14M |
| June 30, 2014 | 39.20M |
| March 31, 2014 | 39.95M |
| December 31, 2013 | 41.94M |
| September 30, 2013 | 43.87M |
| June 30, 2013 | 45.26M |
| March 31, 2013 | 48.26M |
| December 31, 2012 | 50.27M |
| September 30, 2012 | 53.63M |
| June 30, 2012 | 55.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
114.20M
Minimum
Sep 2024
321.06M
Maximum
Sep 2020
247.48M
Average
276.75M
Median
Research and Development Expense (TTM) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 60.73M |
| Alnylam Pharmaceuticals Inc | 1.098B |
| Ionis Pharmaceuticals Inc | 912.60M |
| Arbutus Biopharma Corp | 62.79M |
| Krystal Biotech Inc | 51.42M |